AstraZeneca: sells rights to Losec on some markets

(CercleFinance.com) - AstraZeneca announces that it has agreed to sell the global trade rights (excluding China, the United States and Mexico) for Losec and brands associated with Cheplapharm.


The sale includes drugs containing omeprazole that are marketed by AstraZeneca or its employees, under the names Acimax, Antra, Mepral, Mopral, Omepral and Zoltum.

Under the agreement, Cheplapharm will pay AstraZeneca approximately 243 million dollars, as well as milestone payments of up to 33 million dollars, according to sales in 2021 and 2022.


Copyright (c) 2019 CercleFinance.com. All rights reserved.